Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: Urol Pract. 2023 Sep 26;10(6):656–663. doi: 10.1097/UPJ.0000000000000457

Table 2:

In patients with prostate cancer, adjusted OR of receiving definitive treatment and, of those receiving definitive treatment, adjusted OR of receiving radical prostatectomy

Odds of Receiving Definitive Treatment Of those Receiving Definitive Treatment, Odds of Receiving Radical Prostatectomy

OR (95% CI) OR (95% CI)

Mental Health Disorder
No ref ref
Yes 0.74 (0.66–0.83) 0.81 (0.7–0.95)
Admission for a Mental Health Disorder
No ref ref
Yes 0.67 (0.6–0.75) 1.03 (0.88–1.21)
Age 0.88 (0.88–0.88) 0.82 (0.81–0.82)
Married
Yes ref ref
No 0.75 (0.72–0.77) 0.73 (0.7–0.77)
Urban
No ref ref
Yes 0.88 (0.85–0.91) 1.02 (0.97–1.06)
Race/Ethnicity
White ref ref
Black 0.74 (0.71–0.78) 0.57 (0.54–0.62)
Latino 0.89 (0.83–0.95) 1.25 (1.16–1.36)
Other 0.89 (0.84–0.95) 0.99 (0.91–1.07)
SES
0%-<5% poverty ref ref
5%-<10% poverty 0.91 (0.87–0.95) 1.03 (0.98–1.08)
10%-<20% poverty 0.77 (0.73–0.8) 0.92 (0.88–0.97)
20%-100% poverty 0.73 (0.7–0.77) 0.86 (0.81–0.92)
National Cancer Institute Index
0 ref ref
<2 0.97 (0.93–1) 0.7 (0.67–0.73)
2+ 0.73 (0.7–0.76) 0.48 (0.45–0.51)
Screened
No ref ref
Yes 2.29 (2.21–2.38) 1.19 (1.14–1.25)
Year of Diagnosis of Prostate Cancer
2004–2006 ref ref
2007–2009 1.31 (1.26–1.37) 1.15 (1.09–1.21)
2010–2012 1.61 (1.54–1.67) 1.11 (1.06–1.17)
2013–2015 1.7 (1.62–1.77) 1.28 (1.21–1.35)
T-stage
T1 ref ref
T2 1.04 (1–1.07) 1.11 (1.07–1.15)
T3 1.29 (1.18–1.41) 1.18 (1.07–1.3)
T4 0.5 (0.41–0.61) 0.7 (0.47–1.04)
Gleason Grade
7 ref ref
8–10 0.94 (0.91–0.97) 0.96 (0.92–1)
PSA
<10 ref ref
10.1–20.0 0.81 (0.78–0.84) 0.77 (0.73–0.81)
20.1–50.0 0.55 (0.52–0.58) 0.51 (0.47–0.56)
Unknown 0.38 (0.37–0.4) 2.07 (1.95–2.2)